

UChicago Medicine Comprehensive Cancer Center 2019 ASCO Annual Meeting Presentations

Session Time	Presentation Time	Session Type	Session Title	Presentation Title	Room	Speaker Name	Abst ID	Poster Board
Friday, May 31								
1:00 PM - 3:15 PM		Workshop	How to Initiate and Integrate Clinical Trials Into Your Practice	Workshop Faculty	S405	Trinidad Ajazi		
1:00 PM - 3:15 PM		Workshop	How to Initiate and Integrate Clinical Trials Into Your Practice	Workshop Faculty	S405	Barbara K. Barrett, MS		
3:45 PM - 6:00 PM	3:45 PM - 6:00 PM	Workshop	Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care	Workshop Chair	S405	Fay J. Hlubocky, PhD, MA		
4:30 PM - 5:30 PM	4:30 PM - 5:10 PM	Interactive Case-Based Session	Challenges in Use of Immunotherapy in Non-Small Cell Lung Cancer: Where the Rubber Meets the Road	Case 4: Managing Immune-Related Adverse Events in the Fragile Diabetic Patient	Hall D1	Jyoti D. Patel, MD, FASCO		
Saturday, June 1								
8:00 AM - 9:00 AM		Interactive Case-Based Session	Head and Neck Multidisciplinary Tumor Board: Bread-and-Butter Cases Made Challenging by the New Staging System	"Curable" in Squamous Cell Carcinoma of the Head and Neck Doesn't Necessarily Mean "Easy"	E451	Nishant Agrawal, MD		
8:00 AM - 11:00 AM		Poster Session	Developmental Immunotherapy and Tumor Immunobiology	A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.	Hall A	Raanan Alter, MD (Akash Patnaik, MD, PhD , senior author)	TPS2663	297b
8:00 AM - 11:00 AM		Poster Session	Developmental Therapeutics and Tumor Biology (Nonimmuno)	Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.	Hall A	Mark J. Ratain, MD, FASCO	3013	5
8:00 AM - 11:00 AM		Poster Session	Developmental Therapeutics and Tumor Biology (Nonimmuno)	The i3+3 design for phase I clinical trials.	Hall A	Yuan Ji, PhD	3066	58
8:00 AM - 11:00 AM		Poster Session	Pediatric Oncology	Long term morbidity and mortality among survivors of infant neuroblastoma: A report from the Childhood Cancer Survivor Study (CCSS).	Hall A	Danielle Friedman, MD, MS (Tara Henderson, MD, MPH , senior author)		
8:00 AM - 11:00 AM		Poster Session	Developmental Therapeutics and Tumor Biology (Nonimmuno)	Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer.	Hall A	Padma Sheila Rajagopal, MD	3084	76

1:15 PM - 2:30 PM	2:00 PM - 2:15 PM	Education Session	ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines	Challenges to Access in the United States	S404	Blase N. Polite, MD, MPP, FASCO		
3:00 PM - 4:15 PM		Education Session	ABIM/MOC Oncology Learning and Assessment: The New Alternative MOC Pathway	Panelist	S102	Richard A. Larson, MD		
3:00 PM - 4:30 PM	4:00 PM - 4:12 PM	Clinical Science Symposium	Next-Generation Therapeutics and Biomarkers in Melanoma	Analysis of the Tumor Microenvironment to Guide Immunotherapy	S100bc	Thomas Gajewski, MD, PhD		
Sunday, June 2								
8:00 AM - 11:00 AM	8:00 AM - 8:12 AM	Oral Abstract Session	Pediatric Oncology II	Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.	S504	Giles W. Robinson, MD (Ami Vijay Desai, MD , senior author)	10009	
8:00 AM - 9:30 AM	8:12 AM - 8:24 AM	Clinical Science Symposium	Dissecting Genomic Biomarkers in Head and Neck Cancer	Oral Precancer Biomarkers for Progression	E450	Mark W. Lingen, DDS, PhD		
8:00 AM - 11:00 AM		Poster Session	Breast Cancer—Metastatic	Lasofixifene as a potential treatment for ER+ metastatic breast cancer.	Hall A	Muriel Laine (Geoffrey Greene, PhD , senior author)	1056	137
8:00 AM - 11:00 AM		Poster Session	Breast Cancer—Metastatic	NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).	Hall A	Steven J. Chmura, MD, PhD	TPS1117	189b
8:00 AM - 11:00 AM		Poster Session	Lung Cancer—Non-Small Cell Metastatic	Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).	Hall A	Thomas A. Hensing, MD, MS	9088	411
11:15 AM - 12:45 PM	11:59 AM - 12:09 PM	Poster Discussion Session	Breast Cancer—Metastatic	HER2-Positive Disease: How Far We Have Come?	Hall D2	Olwen Mary Hahn, MD		
1:00 PM - 4:00 PM	3:15 PM - 3:30 PM	Plenary Session	Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.	Hall B1	Hedy L. Kindler, MD, FASCO	LBA4	
4:00 PM - 4:45 PM		Plenary Session	Post-Plenary Discussion: Health Services Research (LBA1)	Panel Speaker	S100a	Blase N. Polite, MD, MPP, FASCO		

5:15 PM - 6:00 PM		Plenary Session	Post-Plenary Clinical Application and Discussion: Pancreatic Cancer (LBA4)	Panel Speaker	S100bc	Hedy L. Kindler, MD, FASCO		
Monday, June 3								
8:00 AM - 9:00 AM	8:00 AM - 8:40 AM	Interactive Case-Based Session	Fostering Moral Resilience: Steps You Can Take to Manage Moral Distress and Burnout in Oncology	Combatting Moral Distress and Burnout in Oncology with Moral Resiliency: What It Is and Why It Matters	E350	Fay J. Hlubocky, PhD, MA		
8:00 AM - 11:00 AM		Poster Session	Gastrointestinal (Noncolorectal) Cancer	Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing 'gFOLFIRINOX' for gastroesophageal adenocarcinoma (GEA).	Hall A	Daniel V.T. Catenacci, MD	4050	155
8:00 AM - 11:00 AM		Poster Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.	Hall A	Olatoyosi Odenike, MD	7030	405
8:00 AM - 11:00 AM		Poster Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	The Transplant Optimization Program (TOP): Implementing a geriatric assessment (GA)-guided interdisciplinary clinic (IDC) prior to allogeneic hematopoietic cell transplantation (HCT) in older adults.	Hall A	Benjamin Avi Derman, MD	7045	420
11:30 AM - 1:00 PM	12:36 PM - 12:48 PM	Poster Discussion Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Awakening the Immune System in DLBCL	E450	Justin Paul Kline, MD		
1:15 PM - 4:15 PM		Poster Session	Genitourinary (Nonprostate) Cancer	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results.	Hall A	Peter H. O'Donnell, MD	4546	372
1:15 PM - 4:15 PM		Poster Session	Symptoms and Survivorship	Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.	Hall A	Caroline Hesko, BS, MPH, MD (Tara Henderson, MD, MPH , senior author) *Merit Award recipient	11563	255
1:15 PM - 4:15 PM		Poster Session	Symptoms and Survivorship	Lower costs of care, improved discharge disposition, and improved survival of advanced cancer patients (ACP) receiving early inpatient palliative care (PC) compared to standard oncologic care (SOC).	Hall A	Christopher Daugherty, MD	11609	301
1:15 PM - 4:15 PM		Poster Session	Symptoms and Survivorship	Till death do us part: Existential loneliness (EL), psychosocial distress, and survival of advanced cancer patients (ACPs), and their spousal caregivers (SCs).	Hall A	Fay J. Hlubocky, PhD, MA	11628	320

4:45 PM - 6:00 PM	5:33 PM - 5:45 PM	Education Session	Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma	Against	Arie Crown Theater	Daniel V.T. Catenacci, MD		
-------------------	-------------------	-------------------	--	---------	--------------------	----------------------------------	--	--

Tuesday, June 4

9:45 AM - 12:45 PM	11:45 AM - 11:57 AM	Oral Abstract Session	Melanoma/ Skin Cancers		Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).	S406	Daniel Olson, MD *Sherwin Family Endowed Merit Award recipient	9506
--------------------	---------------------	-----------------------	---------------------------	--	---	------	---	------

*Bold indicates Comprehensive Cancer Center Faculty